Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma Journal Article


Authors: Offit, K.; Ladanyi, M.; Gangi, M. D.; Ebrahim, S. A. D.; Filippa, D.; Chaganti, R. S. K.
Article Title: Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma
Abstract: Immunohistochemical and immunophenotypic analyses were performed on 278 cases of karyotypically abnormal non-Hodgkin's lymphoma (NHL). Excluding cases of lymphoblastic lymphoma or mycosis fungoides, 20 cases showed evidence of non-B cell lineage. T cell lineage was proven by genotypic and immunophenotypic analyses in 15 of the 20 cases; five were of ambiguous lineage. All of the non-B lineage cases were of diffuse histology with a large cell component (DLCL). Twelve cases expressed the Ki-1 antigen; five of these cases also demonstrated a translocation with a break at 5q35. Patients with Ki-1 positive DLCL and t(5q35) had a younger median age compared with non-B cell DLCL without t(5q35). The Ki-1 positive patients had a higher frequency of skin involvement and lower incidence of bone marrow involvement compared with Ki-1 negative DLCL. Survival analysis was performed on 86 cases of B cell DLCL and 18 cases of non-B cell DLCL which were serially ascertained prior to receiving cytotoxic chemotherapy. Median duration of complete remission was significantly longer in the B cell compared with the non-B cell DLCL groups; there was only a trend for decreased overall survival in the non-B cell group. Among the subset of non-B cell lymphomas, overall survival of patients with Ki-1 expressing DLCL was significantly longer than those with Ki-1 negative DLCL, who had a median survival of less than a year. These results show that immunophenotypic, immunohistochemical, and cytogenetic markers can define subsets of patients with non-B cell lymphomas with differing clinical characteristics and outcome.
Keywords: immunohistochemistry; adolescent; adult; child; clinical article; school child; aged; unclassified drug; human cell; prednisone; doxorubicin; chemotherapy; cytarabine; methotrexate; t-lymphocytes; phenotype; cytology; etoposide; genotype; cyclophosphamide; dexamethasone; vincristine; chromosomes, human, pair 2; t cell lymphoma; nonhodgkin lymphoma; antigens, neoplasm; lymphoma, non-hodgkin; dactinomycin; asparaginase; bleomycin; antigens, cd; cytochemistry; antigens, differentiation; mercaptopurine; middle age; chromosomes, human, pair 5; antigens, cd30; prognosis; human; male; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; translocation (genetics); deazaaminopterin
Journal Title: Leukemia
Volume: 4
Issue: 9
ISSN: 0887-6924
Publisher: Nature Publishing Group  
Date Published: 1990-09-01
Start Page: 625
End Page: 630
Language: English
PUBMED: 2168505
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 January 2020 -- Source: Scopus
Citation Impact
MSK Authors
  1. Kenneth Offit
    788 Offit
  2. Marc Ladanyi
    1326 Ladanyi
  3. Daniel A Filippa
    148 Filippa
  4. Raju S K Chaganti
    391 Chaganti
  5. Salah A. D. Ebrahim
    15 Ebrahim